Dimethyl-celecoxib (DMC), a derivative of celecoxib that lacks cyclooxygenase-2-inhibitory function, potently mimics the anti-tumor effects of celecoxib on Burkitt's lymphoma in vitro and in vivo

Adel Kardosh, Weijun Wang, Jasim Uddin, Nicos A. Petasis, Florence M. Hofman, Thomas C. Chen, Axel H. Schönthal

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

The nonsteroidal anti-inflammatory drug (NSAID) celecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor that has shown some promising results as an anti-cancer drug. However, the question arose as to whether or not its COX-2-inhibitory function is required for its anti-tumorigenic properties. We therefore employed dimethyl-celecoxib (DMC), which is a close structural analog of celecoxib that lacks COX-2-inhibitory function, to investigate this question. By performing a combination of in vitro and in vivo studies with Burkitt's lymphoma cells, we found that DMC potently mimics all of the anti-proliferative and anti-tumorigenic effects of celecoxib. In cell culture, DMC effectively inhibits cell proliferation through the down-regulation of cyclins A and B and the ensuing loss of cyclin-dependent kinase activity. This effect appears to take place in vivo as well and results in significantly (p < .002) reduced tumor growth in experimental animals. Thus, our results demonstrate that the anti-proliferative and anti-tumorigenic properties of celecoxib and DMC are indistinguishable, at least in Burkitt's lymphoma cells, and therefore, that the COX-2-inhibitory function is not required for these effects.

Original languageEnglish (US)
Pages (from-to)571-582
Number of pages12
JournalCancer Biology and Therapy
Volume4
Issue number5
DOIs
StatePublished - Jan 1 2005
Externally publishedYes

Fingerprint

Celecoxib
Burkitt Lymphoma
Cyclooxygenase 2
Neoplasms
Cyclin B
Cyclin A
Cyclin-Dependent Kinases
In Vitro Techniques
Cyclooxygenase 2 Inhibitors
Pharmaceutical Preparations

Keywords

  • Bextra
  • Burkitt's lymphoma
  • CDK
  • Celebrex
  • Celecoxib
  • Cell cycle
  • Cyclins
  • DMC
  • Flurbiprofen
  • Indomethacin
  • Lymphoma
  • NSAIDs
  • Raji
  • Ramos
  • Rofecoxib
  • Sulindac
  • Valdecoxib
  • Vioxx

ASJC Scopus subject areas

  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research

Cite this

Dimethyl-celecoxib (DMC), a derivative of celecoxib that lacks cyclooxygenase-2-inhibitory function, potently mimics the anti-tumor effects of celecoxib on Burkitt's lymphoma in vitro and in vivo. / Kardosh, Adel; Wang, Weijun; Uddin, Jasim; Petasis, Nicos A.; Hofman, Florence M.; Chen, Thomas C.; Schönthal, Axel H.

In: Cancer Biology and Therapy, Vol. 4, No. 5, 01.01.2005, p. 571-582.

Research output: Contribution to journalArticle

Kardosh, Adel ; Wang, Weijun ; Uddin, Jasim ; Petasis, Nicos A. ; Hofman, Florence M. ; Chen, Thomas C. ; Schönthal, Axel H. / Dimethyl-celecoxib (DMC), a derivative of celecoxib that lacks cyclooxygenase-2-inhibitory function, potently mimics the anti-tumor effects of celecoxib on Burkitt's lymphoma in vitro and in vivo. In: Cancer Biology and Therapy. 2005 ; Vol. 4, No. 5. pp. 571-582.
@article{44bab3c434fb461d99beb3bbe574d1c3,
title = "Dimethyl-celecoxib (DMC), a derivative of celecoxib that lacks cyclooxygenase-2-inhibitory function, potently mimics the anti-tumor effects of celecoxib on Burkitt's lymphoma in vitro and in vivo",
abstract = "The nonsteroidal anti-inflammatory drug (NSAID) celecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor that has shown some promising results as an anti-cancer drug. However, the question arose as to whether or not its COX-2-inhibitory function is required for its anti-tumorigenic properties. We therefore employed dimethyl-celecoxib (DMC), which is a close structural analog of celecoxib that lacks COX-2-inhibitory function, to investigate this question. By performing a combination of in vitro and in vivo studies with Burkitt's lymphoma cells, we found that DMC potently mimics all of the anti-proliferative and anti-tumorigenic effects of celecoxib. In cell culture, DMC effectively inhibits cell proliferation through the down-regulation of cyclins A and B and the ensuing loss of cyclin-dependent kinase activity. This effect appears to take place in vivo as well and results in significantly (p < .002) reduced tumor growth in experimental animals. Thus, our results demonstrate that the anti-proliferative and anti-tumorigenic properties of celecoxib and DMC are indistinguishable, at least in Burkitt's lymphoma cells, and therefore, that the COX-2-inhibitory function is not required for these effects.",
keywords = "Bextra, Burkitt's lymphoma, CDK, Celebrex, Celecoxib, Cell cycle, Cyclins, DMC, Flurbiprofen, Indomethacin, Lymphoma, NSAIDs, Raji, Ramos, Rofecoxib, Sulindac, Valdecoxib, Vioxx",
author = "Adel Kardosh and Weijun Wang and Jasim Uddin and Petasis, {Nicos A.} and Hofman, {Florence M.} and Chen, {Thomas C.} and Sch{\"o}nthal, {Axel H.}",
year = "2005",
month = "1",
day = "1",
doi = "10.4161/cbt.4.5.1699",
language = "English (US)",
volume = "4",
pages = "571--582",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "5",

}

TY - JOUR

T1 - Dimethyl-celecoxib (DMC), a derivative of celecoxib that lacks cyclooxygenase-2-inhibitory function, potently mimics the anti-tumor effects of celecoxib on Burkitt's lymphoma in vitro and in vivo

AU - Kardosh, Adel

AU - Wang, Weijun

AU - Uddin, Jasim

AU - Petasis, Nicos A.

AU - Hofman, Florence M.

AU - Chen, Thomas C.

AU - Schönthal, Axel H.

PY - 2005/1/1

Y1 - 2005/1/1

N2 - The nonsteroidal anti-inflammatory drug (NSAID) celecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor that has shown some promising results as an anti-cancer drug. However, the question arose as to whether or not its COX-2-inhibitory function is required for its anti-tumorigenic properties. We therefore employed dimethyl-celecoxib (DMC), which is a close structural analog of celecoxib that lacks COX-2-inhibitory function, to investigate this question. By performing a combination of in vitro and in vivo studies with Burkitt's lymphoma cells, we found that DMC potently mimics all of the anti-proliferative and anti-tumorigenic effects of celecoxib. In cell culture, DMC effectively inhibits cell proliferation through the down-regulation of cyclins A and B and the ensuing loss of cyclin-dependent kinase activity. This effect appears to take place in vivo as well and results in significantly (p < .002) reduced tumor growth in experimental animals. Thus, our results demonstrate that the anti-proliferative and anti-tumorigenic properties of celecoxib and DMC are indistinguishable, at least in Burkitt's lymphoma cells, and therefore, that the COX-2-inhibitory function is not required for these effects.

AB - The nonsteroidal anti-inflammatory drug (NSAID) celecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor that has shown some promising results as an anti-cancer drug. However, the question arose as to whether or not its COX-2-inhibitory function is required for its anti-tumorigenic properties. We therefore employed dimethyl-celecoxib (DMC), which is a close structural analog of celecoxib that lacks COX-2-inhibitory function, to investigate this question. By performing a combination of in vitro and in vivo studies with Burkitt's lymphoma cells, we found that DMC potently mimics all of the anti-proliferative and anti-tumorigenic effects of celecoxib. In cell culture, DMC effectively inhibits cell proliferation through the down-regulation of cyclins A and B and the ensuing loss of cyclin-dependent kinase activity. This effect appears to take place in vivo as well and results in significantly (p < .002) reduced tumor growth in experimental animals. Thus, our results demonstrate that the anti-proliferative and anti-tumorigenic properties of celecoxib and DMC are indistinguishable, at least in Burkitt's lymphoma cells, and therefore, that the COX-2-inhibitory function is not required for these effects.

KW - Bextra

KW - Burkitt's lymphoma

KW - CDK

KW - Celebrex

KW - Celecoxib

KW - Cell cycle

KW - Cyclins

KW - DMC

KW - Flurbiprofen

KW - Indomethacin

KW - Lymphoma

KW - NSAIDs

KW - Raji

KW - Ramos

KW - Rofecoxib

KW - Sulindac

KW - Valdecoxib

KW - Vioxx

UR - http://www.scopus.com/inward/record.url?scp=25144506566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25144506566&partnerID=8YFLogxK

U2 - 10.4161/cbt.4.5.1699

DO - 10.4161/cbt.4.5.1699

M3 - Article

C2 - 15846081

AN - SCOPUS:25144506566

VL - 4

SP - 571

EP - 582

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 5

ER -